造血干细胞移植在先天性溶血性贫血治疗中的应用  

The application of hematopoietic stem cell transplantation in treatment of congenital hemolytic anemia

作　　者：赖永榕[1] 

机构地区：[1]广西医科大学第一附属医院血液内科,南宁530021

出　　处：《中国实用内科杂志》2012年第5期344-346,共3页Chinese Journal of Practical Internal Medicine

摘　　要：造血干细胞移植(HSCT)是目前惟一能治愈先天性溶血性贫血(如重型地中海贫血和鐮状细胞贫血)的治疗方法。HLA相合同胞供者移植治疗儿童患者的总生存(OS)率超过90%,无事件生存(EFS)率超过80%。无关供者移植使更多无HLA相合同胞供者的患者获得移植机会。Summary ：Hematopoietic stem cell transplantation （HSCT） remains the only treatment method that can cure congenital he- molytic anemia such as severe thalassemia and sickle cell anemia （SCA） at present. The overall survival （OS） is over 90% in children treated with HLA-identical sibling donor transplantation, while event-free survival （EFS） is over 80%. The e- vent-free donor transplantation enables more patients without HLA-identical sibling donors to obtain transplantation chances.

关 键 词：造血干细胞移植 地中海贫血 镰状细胞贫血 

分 类 号：R551[医药卫生—血液循环系统疾病]